nVSM (dizziness treatment system)

2022: Entry into the market of a device that treats vertigo

On September 7, 2022, Otolith Labs announced the closure of a $20 million Series A funding round, thanks to which the company was able to bring a device for the treatment of chronic dizziness to the market.

The manufacturer plans to use the funds to support ongoing clinical programs, obtain regulatory approvals and launch commercial products in different countries.

nVSM (dizziness treatment system)

The company is developing a prescription wearable device to treat chronic dizziness. It uses non-invasive vestibular masking (nVSM) technology. In 2021, the device received FDA certification as a breakthrough device.

Otolith Labs has developed its nVSM technology for immediate symptom relief. She applies localized mechanical stimulation of the vestibular apparatus through calibration vibrations.

The closure of our Series A funding, led by expert investor group Morningside and the continued support of our existing investors, underscores the growing momentum for the first wearable solution to a debilitating problem that is negatively impacting millions of Americans, said Sam Owen, CEO and founder of Otolith Labs. Participants in our pilot studies reported instant relief of dizziness symptoms. Data from these studies support our plan to release our nVSM technology as an effective and well-tolerated therapy for chronic dizziness. We founded the company to improve people's lives, and with the support of Morningside, we are on track to make this vision a reality.

Otolith's pilot studies of about 100 people demonstrated what the company called an "immediate and reliable" therapeutic effect compared to placebo. Subjects in the active group were more than three times more likely to report improved symptoms than those in the placebo group, the company said.^[1]

Notes

Шаблон:Remarks